Aro Biotherapeutics CEO and leadership

Sue Dillon, PhD, brings 30 years of experience in executive leadership roles at pharmaceutical and biotech companies to Aro Biotherapeutics. During her more than 16 year career at Johnson & Johnson, Sue led global Immunology R&D, and achieved numerous regulatory approvals for innovative antibody products for autoimmune diseases including REMICADE®, SIMPONI®, STELARA® and TREMFYA®. She also built a robust Immunology development portfolio through internal discovery and external licensing, and championed research into the emerging areas of the microbiome and immune repertoire profiling. Multi-disciplinary teams under Sue’s leadership were twice recognized with the Prix Galien Award for PROMACTA® and STELARA®, each first-in-class medicines. Sue received her PhD in Immunology from Thomas Jefferson University in Philadelphia and completed a postdoctoral fellowship in Immunology at Duke University. She was named by FierceBiotech as one of the “Top Women in Biotech” in 2013.

Karyn O'Neil is a co-founder of Aro Biotherapeutics, focused on Centyrins a unique protein platform designed to enable optimized delivery of multiple drug payloads including nucleic acid and genetic therapeutics for diseases with high unmet need. Previously, Karyn spent 16 years at Centocor/J&J in various leadership roles including Director of Antibody Therapeutics and CSO/Venture leader for Centyrex where she led the scientific team focused on developing the Centyrin platform. Karyn earned her PhD is Structural Biology and Protein Biophysics from the University of Pennsylvania and Bachelor of Science and Master of Science degrees in Chemistry from the University of Delaware. She has authored more than 55 scientific publications and is an inventor on more than 30 patents.

C-Level executive with proven results in delivering innovation to market, growing revenue, optimizing operations, and leading change in both large and small organizations. Known as a strategic thinker who drives business goals in the Life Sciences and Aerospace & Defense fields, I leverage an expert blend of technical, operational, executive, people leadership skills to bring value to businesses. Throughout my career, I have been a trusted partner who forges cohesive, motivated teams, collaborates across disciplines, and influences key stakeholders.

Expertise that adds value at every business stage:

• Discern possibilities from market needs

• Craft strategies from disparate ideas

• Operationalize concept development through delivery

• Decipher opportunities from financial analyses

• Synthesize actionable business cases from broad ideas

• Customize HR systems to engage employees

• Optimize business processes for enhanced profits

• Secure capital and resources for critical programs

Contact info: mvlaurenzi@gmail.com

Scott Greenberg is a Chief Business Officer at Aro Biotherapeutics and is based in Philadelphia, Pennsylvania. He has worked as Senior Director, Project Leader, Lymphoma at CELGENE CORP; Director, Principal to the CEO at CELGENE CORP; and Vice President, Head of Operations at Roivant Sciences. Scott attended University of Pennsylvania between 1997 and 2001 and Harvard Business School between 2004 and 2006.

Sue Dillon, PhD, brings 30 years of experience in executive leadership roles at pharmaceutical and biotech companies to Aro Biotherapeutics. During her more than 16 year career at Johnson & Johnson, Sue led global Immunology R&D, and achieved numerous regulatory approvals for innovative antibody products for autoimmune diseases including REMICADE®, SIMPONI®, STELARA® and TREMFYA®. She also built a robust Immunology development portfolio through internal discovery and external licensing, and championed research into the emerging areas of the microbiome and immune repertoire profiling. Multi-disciplinary teams under Sue’s leadership were twice recognized with the Prix Galien Award for PROMACTA® and STELARA®, each first-in-class medicines. Sue received her PhD in Immunology from Thomas Jefferson University in Philadelphia and completed a postdoctoral fellowship in Immunology at Duke University. She was named by FierceBiotech as one of the “Top Women in Biotech” in 2013.

Karyn O'Neil is a co-founder of Aro Biotherapeutics, focused on Centyrins a unique protein platform designed to enable optimized delivery of multiple drug payloads including nucleic acid and genetic therapeutics for diseases with high unmet need. Previously, Karyn spent 16 years at Centocor/J&J in various leadership roles including Director of Antibody Therapeutics and CSO/Venture leader for Centyrex where she led the scientific team focused on developing the Centyrin platform. Karyn earned her PhD is Structural Biology and Protein Biophysics from the University of Pennsylvania and Bachelor of Science and Master of Science degrees in Chemistry from the University of Delaware. She has authored more than 55 scientific publications and is an inventor on more than 30 patents.

Karyn O'Neil is a co-founder of Aro Biotherapeutics, focused on Centyrins a unique protein platform designed to enable optimized delivery of multiple drug payloads including nucleic acid and genetic therapeutics for diseases with high unmet need. Previously, Karyn spent 16 years at Centocor/J&J in various leadership roles including Director of Antibody Therapeutics and CSO/Venture leader for Centyrex where she led the scientific team focused on developing the Centyrin platform. Karyn earned her PhD is Structural Biology and Protein Biophysics from the University of Pennsylvania and Bachelor of Science and Master of Science degrees in Chemistry from the University of Delaware. She has authored more than 55 scientific publications and is an inventor on more than 30 patents.